Viktoria Gavrilina / Shutterstock.com
Pluristem develops therapies using cells from the placenta that have been cultured in a unique way. LSIPR finds out how the company protects and nourishes its technologies.
Several years after scientists found a way to harvest stem cells efficiently from the placenta after birth, companies are turning to it increasingly as a source for cell-based therapies.
The organ that for nine months keeps both mother and baby healthy during pregnancy and which, further research suggests, also plays a role in their long-term health, is a rich source of stem cells.
However, so understudied is the placenta that the Maryland-based Eunice Kennedy Shriver National Institute of Child Health and Human Development (NIH) has announced a Human Placenta Project, an initiative aimed at “unlocking the secrets” of the one-pound (500g) organ.
You need a subscription to continue reading this content.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
News stories up to a week old and feature articles on the day of publication are accessible with a BASIC FREE ACCOUNT.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’; and for basic access to the latest news on the website and weekly email news alerts choose the 'BASIC FREE ACCOUNT' registration.
Pluristern; stem cells; cell-based therapies; NIH